{"id":"bazedoxifene-bza-20","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hot flashes"},{"rate":"5-10%","effect":"Vaginal discharge"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This dual activity allows bazedoxifene to modulate the effects of estrogen in various tissues, potentially reducing the risk of osteoporosis and other estrogen-related conditions. By selectively activating estrogen receptor beta, bazedoxifene may also have beneficial effects on bone density and cardiovascular health.","oneSentence":"Bazedoxifene acts as a selective estrogen receptor modulator (SERM) with agonist activity on the estrogen receptor beta and antagonist activity on the estrogen receptor alpha.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:22.217Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment and prevention of postmenopausal osteoporosis"}]},"trialDetails":[{"nctId":"NCT04821141","phase":"PHASE2","title":"Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2021-12-14","conditions":"Risk Reduction, Breast Cancer","enrollment":120},{"nctId":"NCT00774267","phase":"","title":"Study Evaluating Changes In Mammographic Breast Density","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Osteoporosis","enrollment":507},{"nctId":"NCT00384072","phase":"PHASE3","title":"Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-05","conditions":"Postmenopause, Osteoporosis","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":53,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"bazedoxifene BZA-20","genericName":"bazedoxifene BZA-20","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bazedoxifene, specifically the 20 mg dose, is being studied in combination with conjugated estrogens for the risk reduction of breast cancer, osteoporosis, and postmenopausal conditions. This combination is being investigated in a Phase IIb trial, as per the study NCT04821141 conducted by the University of Kansas Medical Center.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}